EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

Dominick J Angiolillo, Davide Cao, Samantha Sartori, Usman Baber, George Dangas, Zhongjie Zhang, Birgit Vogel, Vijay Kunadian, Carlo Briguori, David J Cohen, Timothy Collier, Dariusz Dudek und 21 weitere

JACC: Cardiovascular Interventions · 2023-10 · 16 (20) · 2514-2524

DOI: 10.1016/j.jcin.2023.08.019 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023-10. Verfasst von Dominick J Angiolillo und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: AstraZeneca Gothenburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases. OBJECTIVES: The authors sought to evaluate the incidence, predictors, and outcomes of dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention (PCI). METHODS: In the TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) trial, after 3 months of ticagrelor plus aspirin, patients were maintained on ticagrelor and randomized to aspirin or placebo for 1 year. The occurrence of dyspnea associated with ticagrelor discontinuation was evaluated among all patients enrolled in the trial. A landmark analysis was performed at 3 months after PCI, that is, the time of randomization. Predictors of dyspnea-related ticagrelor discontinuation were obtained from multivariable Cox regression with stepwise selection of candidate variables. RESULTS: The incidence of dyspnea-related ticagrelor discontinuation was 6.4% and 9.1% at 3 and 15 months after PCI, respectively. Independent predictors included Asian race (lower risk), smoking, prior PCI, hypercholesterolemia, prior coronary artery bypass, peripheral artery disease, obesity, and older age. Among 179 patients who discontinued ticagrelor because of dyspnea after randomization, ticagrelor monotherapy was not associated with a higher risk of subsequent ischemic events (composite of all-cause death, myocardial infarction, or stroke) compared with ticagrelor plus aspirin (5.0% vs 7.1%; P = 0.566). CONCLUSIONS: In the TWILIGHT trial, dyspnea-related ticagrelor discontinuation occurred in almost 1 in 10 patients and tended to occur earlier rather than late after PCI. Several demographic and clinical conditions predicted its occurrence, and their assessment may help identify subjects at risk for therapy nonadherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsPercutaneous Coronary InterventionHumansTicagrelorHemorrhageTreatment OutcomeDrug Therapy, CombinationAspirinDyspnea

Stichwörter der Autor:innen

PCIantiplatelet therapy discontinuationaspirindyspneaticagrelor monotherapy

Substanzen

TicagrelorPlatelet Aggregation InhibitorsAspirin

Autor:innen und Institutionen

  • Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
  • The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Cardiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
  • Mediterranea Cardiocentro, Naples, Italy.

Förderung

  • AstraZeneca Gothenburg

Zitieren

APA

Angiolillo, D. J., Cao, D., Sartori, S., Baber, U., Dangas, G., Zhang, Z., Vogel, B., Kunadian, V., Briguori, C., Cohen, D. J., Collier, T., Dudek, D., Gibson, M., Gil, R., Huber, K., Kaul, U., Kornowski, R., Krucoff, M. W., Ielasi, A., …, & Mehran, R. (2023). Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 16(20), 2514-2524. https://doi.org/10.1016/j.jcin.2023.08.019

Vancouver

Angiolillo DJ, Cao D, Sartori S, Baber U, Dangas G, Zhang Z, et al. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2023;16(20):2514-2524. doi:10.1016/j.jcin.2023.08.019

BibTeX
@article{Angiolillo2023,
  author = {Angiolillo, Dominick J and Cao, Davide and Sartori, Samantha and Baber, Usman and Dangas, George and Zhang, Zhongjie and Vogel, Birgit and Kunadian, Vijay and Briguori, Carlo and Cohen, David J and Collier, Timothy and Dudek, Dariusz and Gibson, Michael and Gil, Robert and Huber, Kurt and Kaul, Upendra and Kornowski, Ran and Krucoff, Mitchell W and Ielasi, Alfonso and Stefanini, Giulio G and Pivato, Carlo A and Mehta, Shamir and Moliterno, David J and Ohman, E Magnus and Escaned, Javier and Sardella, Gennaro and Sharma, Samin K and Shlofmitz, Richard and Weisz, Giora and Witzenbichler, Bernhard and Steg, P Gabriel and Pocock, Stuart and Mehran, Roxana},
  title = {Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  volume = {16},
  number = {20},
  pages = {2514--2524},
  doi = {10.1016/j.jcin.2023.08.019}
}
Kostenlos starten →